You are here: Industry Insights > Celgene

News List

Celgene's Revlimid tops Medicare spending, shares the price-hike title with Pfizer's Lyrica fiercepharma
March 18, 2019
One cancer drug, two diabetes drugs and two next-generation blood thinners topped the Medicare Part D charts for 2017—all with sales of more than $2.5 billion apiece. But two other numbers stood out at the top of the list: the 15%-plus price increases for
Celgene dodges Alvogen bid to overturn Revlimid patent PharmaSources/biopharmadive
March 18, 2019
Revlimid (lenalidomide) is a crucial drug for Celgene and its nearly $10 billion in annual revenue is a key part of Bristol-Myers' deal to buy the storied biotech.
Celgene survives Alvogen's attempt for inter partes review of Revlimid patent in US firstwordpharma
March 15, 2019
The US Patent Office's Patent Trial and Appeal Board (PTAB) on Thursday rebuffed Alvogen's filing requesting an inter partes review of a patent covering Celgene's Revlimid (lenalidomide).
BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge fiercepharma
March 15, 2019
Much of the investor doubt surrounding Bristol-Myers Squibb’s $74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in th
Bristol-Myers Squibb CEO insists proposed Celgene purchase not a "defensive deal" firstwordpharma
March 13, 2019
Bristol-Myers Squibb CEO Giovanni Caforio reiterated that the company's proposed $74-billion acquisition of Celgene is not designed to fend-off a takeover of the company. This "is not [a] defensive deal," Caforio said, as the drugmaker looks to persuade i
Celgene files for EU approval of ozanimod in relapsing-remitting MS, with US re-submission on track firstwordpharma
March 12, 2019
Celgene on Monday announced the filing of a marketing application in Europe seeking approval of the oral, sphingosine 1-phosphate receptor modulator ozanimod for the treatment of relapsing-remitting multiple sclerosis.
Celgene’s fedratinib gets FDA priority review for myelofibrosis pharmaceutical-technology
March 08, 2019
Celgene has secured the US Food and Drug Administration (FDA) priority review status for the new drug application (NDA) of fedratinib to treat patients with myelofibrosis.
FDA grants priority review to filing for Celgene's JAK2 inhibitor fedratinib in myelofibrosis firstwordpharma
March 06, 2019
Celgene on Tuesday announced that the FDA granted priority review to a marketing application seeking approval of the JAK2 inhibitor fedratinib for the treatment of patients with myelofibrosis, setting a target action date of September 3.
Celgene slipped up repeatedly last year. So why did CEO Mark Alles get a raise? fiercepharma
March 06, 2019
Considering that so much of a CEO’s pay is pegged to performance, Celgene CEO Mark Alles doesn't seem a likely candidate for a raise in 2018—not after the company stumbled repeatedly last year.
Adagene to evaluate dynamic precision library platform with Celgene biospectrumasia
March 04, 2019
Adagene will use its Dynamic Precision Library, to discover antibodies against targets chosen by Celgene

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page